1. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. (December 2018) Authors: Koga, Takamasa; Kobayashi, Yoshihisa; Tomizawa, Kenji; Suda, Kenichi; Kosaka, Takayuki; Sesumi, Yuichi; Fujino, Toshio; Nishino, Masaya; Ohara, Shuta; Chiba, Masato; Shimoji, Masaki; Takemoto, Toshiki; Suzuki, Makoto; Jänne, Pasi A.; Mitsudomi, Tetsuya Journal: Lung cancer Issue: Volume 126(2018) Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance. Issue 10 (12th March 2021) Authors: Nishino, Masaya; Suda, Kenichi; Koga, Takamasa; Ohara, Shuta; Fujino, Toshio; Soh, Junichi; Tirunagaru, Vijaya; Vellanki, Avanish; Doebele, Robert C.; Mitsudomi, Tetsuya Journal: Thoracic cancer Issue: Volume 12:Issue 10(2021) Page Start: 1511 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). (August 2016) Authors: Shimoji, Masaki; Shimizu, Shigeki; Sato, Katsuaki; Suda, Kenichi; Kobayashi, Yoshihisa; Tomizawa, Kenji; Takemoto, Toshiki; Mitsudomi, Tetsuya Journal: Lung cancer Issue: Volume 98(2016) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). (August 2016) Authors: Shimoji, Masaki; Shimizu, Shigeki; Sato, Katsuaki; Suda, Kenichi; Kobayashi, Yoshihisa; Tomizawa, Kenji; Takemoto, Toshiki; Mitsudomi, Tetsuya Journal: Lung cancer Issue: Volume 98(2016) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. (October 2017) Authors: Tomizawa, Kenji; Shimizu, Shigeki; Ohara, Shuta; Fujino, Toshio; Nishino, Masaya; Sesumi, Yuichi; Kobayashi, Yoshihisa; Sato, Katsuaki; Chiba, Masato; Shimoji, Masaki; Suda, Kenichi; Takemoto, Toshiki; Mitsudomi, Tetsuya Journal: Lung cancer Issue: Volume 112(2017) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DNA shedding in non-small-cell lung cancer: useful to assess?. Issue 2 (February 2018) Authors: Suda, Kenichi Journal: Lancet Issue: Volume 6:Issue 2(2018) Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. (April 2021) Authors: Ohara, Shuta; Suda, Kenichi; Fujino, Toshio; Hamada, Akira; Koga, Takamasa; Nishino, Masaya; Chiba, Masato; Shimoji, Masaki; Takemoto, Toshiki; Soh, Junichi; Mitsudomi, Tetsuya Journal: Lung cancer Issue: Volume 154(2021) Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. (February 2017) Authors: Sesumi, Yuichi; Suda, Kenichi; Mizuuchi, Hiroshi; Kobayashi, Yoshihisa; Sato, Katsuaki; Chiba, Masato; Shimoji, Masaki; Tomizawa, Kenji; Takemoto, Toshiki; Mitsudomi, Tetsuya Journal: Lung cancer Issue: Volume 104(2017) Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. (December 2018) Authors: Nishino, Masaya; Suda, Kenichi; Kobayashi, Yoshihisa; Ohara, Shuta; Fujino, Toshio; Koga, Takamasa; Chiba, Masato; Shimoji, Masaki; Tomizawa, Kenji; Takemoto, Toshiki; Mitsudomi, Tetsuya Journal: Lung cancer Issue: Volume 126(2018) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. (January 2019) Authors: Agustoni, Francesco; Suda, Kenichi; Yu, Hui; Ren, Shengxiang; Rivard, Christopher J.; Ellison, Kim; Caldwell, Charles; Rozeboom, Leslie; Brovsky, Kristine; Hirsch, Fred R. Journal: Cancer treatment reviews Issue: Volume 72(2019) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗